Thromboangiitis Obliterans (Buerger’s): Signs, Diagnosis, Care

Thromboangiitis obliterans, also known as

Buerger’s disease

, is a rare, non-atherosclerotic segmental inflammatory disease that affects small- and medium-sized arteries and veins, primarily in the distal extremities of the upper and lower limbs. It leads to progressive occlusion through thrombosis and inflammation, resulting in ischemia, pain, ulceration, and potential gangrene. Strongly associated with tobacco use, this condition predominantly impacts young male smokers under 45 years, though it can affect women and non-smokers rarely.

What is thromboangiitis obliterans?

**Thromboangiitis obliterans (TAO)**, or Buerger’s disease, involves recurrent acute and chronic inflammation of the arteries and veins in the arms and legs, causing thrombus formation without significant involvement of the vessel walls. Unlike atherosclerosis, TAO spares proximal large vessels and features a distinctive histopathology with neutrophil infiltration in acute phases, organizing thrombus in subacute stages, and perivascular fibrosis chronically. The disease typically starts distally in digital, palmar, and plantar arteries, progressing proximally with “corkscrew” collaterals visible on angiography. It affects 0.25-24 per 100,000 population, with higher incidence in regions with high tobacco use like Asia and the Middle East.

Pathogenesis implicates tobacco exposure as the primary trigger, possibly through hypersensitivity to tobacco antigens or direct endothelial toxicity. Genetic factors like HLA haplotypes may predispose certain populations, but no single cause is confirmed. Inflammation leads to vessel occlusion, ischemia, and neurologic symptoms like paresthesia due to nerve involvement.

Who gets thromboangiitis obliterans?

TAO primarily affects individuals aged 20-45 years, with a strong male predominance (3:1 to 9:1 ratio), though female cases are rising with increased smoking. Over 90-95% of patients are current or recent tobacco users, including cigarettes, beedis, or cannabis. It is more prevalent in Ashkenazi Jews, Indians, Koreans, and Japanese, but occurs worldwide.

Risk factors include:

• Prolonged tobacco exposure (pack-years >20).
• Male gender and young age (<45).
• Genetic predisposition in certain ethnic groups.
• Possible hypercoagulability or immune dysregulation.

Rare cases occur in non-smokers, suggesting multifactorial etiology.

Clinical features of thromboangiitis obliterans

Symptoms arise from distal ischemia and typically develop gradually. Initial manifestations include:

• Claudication: Foot arch or calf pain on walking, hand/forearm pain on use.
• Raynaud phenomenon: Cold-induced pallor, cyanosis, rubor in digits.
• Paresthesia, numbness, tingling starting distally.

Progression leads to rest pain, non-healing ulcers on toes/fingers, and gangrene. Superficial migratory thrombophlebitis affects ~40-50% of cases. Skin changes include cyanosis, hyperemia, and livedo reticularis.

Stage	Symptoms	Findings
Early	Intermittent claudication, Raynaud’s	Normal pulses, distal coolness
Intermediate	Rest pain, ulcers	Absent distal pulses, trophic changes
Advanced	Gangrene, necrosis	Cyanosis, infection risk

Diagnosis of thromboangiitis obliterans

Diagnosis relies on clinical criteria (Shionoya’s): age <50, distal ischemia, tobacco use, exclusion of other causes, and typical angiography.

Physical exam: Absent distal pulses, color changes (pale on elevation, red on dependency), cool extremities.

Investigations:

• Ankle-brachial index (ABI): <0.7 distally.
• Angiography: Segmental occlusions, “corkscrew collaterals”, sparing of proximal vessels.
• Ultrasound/Doppler: Reduced flow, no proximal atherosclerosis.
• Labs: Normal ESR/CRP, negative ANA/RF, rule out diabetes, hypercoagulability.
• Echocardiography: Exclude emboli source.
• Biopsy: Rarely needed; shows inflammatory thrombus, intact elastic lamina.

Differential diagnosis

TAO mimics:

• Atherosclerosis (older age, proximal disease).
• Embolic disease (atrial fibrillation).
• Autoimmune vasculitis (e.g., SLE, positive serology).
• Hypercoagulable states (e.g., antiphospholipid).
• Ergotism, cocaine use.

Key differentiator: young smoker with distal disease and normal acute phase reactants.

Management and treatment of thromboangiitis obliterans

Smoking cessation is paramount; it halts progression in 94% of compliant patients. Pharmacotherapy (varenicline, bupropion) and counseling aid quitting.

Conservative: Wound care, pain control (opioids, gabapentin), vasodilators (iloprost), antiplatelets (aspirin).

Medical: Prostaglandins (iloprost IV) improve healing; bosentan reduces amputations. Pneumatic compression, hyperbaric oxygen adjunctive.

Surgical: Bypass rare due to distal disease; sympathectomy, spinal cord stimulation for pain. Amputation for gangrene.

Vascular endothelial growth factor (VEGF) gene therapy shows promise in trials.

Complications

• Ulceration and gangrene requiring amputation (25-40%).
• Chronic pain and disability.
• Superficial thrombophlebitis.
• Secondary infection.

Prevention

Avoid all tobacco products; early recognition in at-risk groups. Screen young smokers with limb symptoms.

Prognosis

Excellent with cessation (5-year limb salvage >90%); poor without (40% major amputation). Relapse common with resumed smoking.

Frequently asked questions

What causes Buerger’s disease?

Tobacco use is the main trigger, causing vascular inflammation and thrombosis.

Can Buerger’s disease be cured?

Not curable, but cessation stops progression; supportive treatments manage symptoms.

Does quitting smoking reverse Buerger’s?

It halts worsening and allows collateral growth, but existing damage persists.

Who is at risk for thromboangiitis obliterans?

Young adult smokers, especially males under 45.

Is amputation inevitable?

No, only ~25% with cessation; higher without.